Quarterly report pursuant to Section 13 or 15(d)

STOCKHOLDERS' EQUITY

v3.20.2
STOCKHOLDERS' EQUITY
6 Months Ended
Sep. 30, 2020
STOCKHOLDERS' EQUITY  
NOTE 16 - STOCKHOLDERS' EQUITY

NOTE 16 - SHAREHOLDERS’ EQUITY

 

During the six months ended September 30, 2020, no stock options were exercised and during the six months ended September 30, 2019, nonqualified stock options to purchase 50,000 shares were exercised at a strike price of $1.98 per share for total proceeds of $99.

 

On October 6, 2017, the Company awarded restricted stock grants totalling 3,900,000 shares of its common stock to 16 employees and awarded nonqualified stock options to purchase an aggregate of 360,000 shares of its common stock to two employees. Of the 3,900,000 shares awarded pursuant to the restricted stock grant awards, 1,200,000 shares were subject to two-year vesting conditions and 2,700,000 shares are subject to three-year vesting conditions. Shares of restricted stock have the same dividend and voting rights as common stock while options do not. All awards were issued at the fair value of the underlying shares at the grant date. All of the nonqualified stock options are subject to three-year vesting conditions. The Company recorded stock-based compensation expense for restricted stock grants and stock options in the amount of $781 and $1,554during the three and six months ended September 30, 2019, respectively. The Company recorded stock-based compensation expense for restricted stock grants and stock options in the amount of $530 and $1,055 during the three and six months ended September 30, 2020, respectively.